ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

Leukemia. 2014 Oct;28(10):2090-2. doi: 10.1038/leu.2014.168. Epub 2014 May 23.

Authors

L Falchi¹, M Mehrotra², K J Newberry¹, L M Lyle¹, G Lu², K P Patel², R Luthra², U Popat³, S Verstovsek¹

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Cytogenetics
ETS Translocation Variant 6 Protein
Eosinophilia / metabolism*
Female
Humans
Mutation
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / therapy*
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Proto-Oncogene Proteins c-ets / genetics*
Repressor Proteins / genetics*
Sorafenib
Stem Cell Transplantation*
Transplantation, Homologous
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Phenylurea Compounds
Proto-Oncogene Proteins c-ets
Repressor Proteins
Niacinamide
Sorafenib
FLT3 protein, human
fms-Like Tyrosine Kinase 3

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States